Current treatments for patients with newly diagnosed or early relapsed MM include various combinations of proteosome inhibitors (PIs), immunomodulatory drugs (IMiDs) and monoclonal antibodies (mAbs) targeting CD38, as well as autologous stem cell transplantation in select fit patients. This evidence concerns the gene CD38 and Miyoshi myopathy.